QQQ   269.33 (-0.36%)
AAPL   447.65 (-0.72%)
MSFT   206.20 (-0.98%)
FB   265.44 (+0.93%)
GOOGL   1,491.97 (-0.32%)
AMZN   3,132.80 (-0.49%)
NVDA   442.55 (-0.91%)
CGC   17.62 (-1.73%)
BABA   251.73 (+1.45%)
TSLA   1,399.49 (-1.35%)
GE   6.90 (+3.45%)
MU   48.94 (-0.43%)
AMD   80.01 (-2.71%)
T   30.55 (+1.16%)
F   7.30 (+2.96%)
ACB   10.12 (-0.98%)
GILD   68.69 (+0.26%)
NFLX   476.66 (-1.39%)
DIS   131.46 (+2.07%)
BAC   27.43 (+3.28%)
BA   187.00 (+4.23%)
QQQ   269.33 (-0.36%)
AAPL   447.65 (-0.72%)
MSFT   206.20 (-0.98%)
FB   265.44 (+0.93%)
GOOGL   1,491.97 (-0.32%)
AMZN   3,132.80 (-0.49%)
NVDA   442.55 (-0.91%)
CGC   17.62 (-1.73%)
BABA   251.73 (+1.45%)
TSLA   1,399.49 (-1.35%)
GE   6.90 (+3.45%)
MU   48.94 (-0.43%)
AMD   80.01 (-2.71%)
T   30.55 (+1.16%)
F   7.30 (+2.96%)
ACB   10.12 (-0.98%)
GILD   68.69 (+0.26%)
NFLX   476.66 (-1.39%)
DIS   131.46 (+2.07%)
BAC   27.43 (+3.28%)
BA   187.00 (+4.23%)
QQQ   269.33 (-0.36%)
AAPL   447.65 (-0.72%)
MSFT   206.20 (-0.98%)
FB   265.44 (+0.93%)
GOOGL   1,491.97 (-0.32%)
AMZN   3,132.80 (-0.49%)
NVDA   442.55 (-0.91%)
CGC   17.62 (-1.73%)
BABA   251.73 (+1.45%)
TSLA   1,399.49 (-1.35%)
GE   6.90 (+3.45%)
MU   48.94 (-0.43%)
AMD   80.01 (-2.71%)
T   30.55 (+1.16%)
F   7.30 (+2.96%)
ACB   10.12 (-0.98%)
GILD   68.69 (+0.26%)
NFLX   476.66 (-1.39%)
DIS   131.46 (+2.07%)
BAC   27.43 (+3.28%)
BA   187.00 (+4.23%)
QQQ   269.33 (-0.36%)
AAPL   447.65 (-0.72%)
MSFT   206.20 (-0.98%)
FB   265.44 (+0.93%)
GOOGL   1,491.97 (-0.32%)
AMZN   3,132.80 (-0.49%)
NVDA   442.55 (-0.91%)
CGC   17.62 (-1.73%)
BABA   251.73 (+1.45%)
TSLA   1,399.49 (-1.35%)
GE   6.90 (+3.45%)
MU   48.94 (-0.43%)
AMD   80.01 (-2.71%)
T   30.55 (+1.16%)
F   7.30 (+2.96%)
ACB   10.12 (-0.98%)
GILD   68.69 (+0.26%)
NFLX   476.66 (-1.39%)
DIS   131.46 (+2.07%)
BAC   27.43 (+3.28%)
BA   187.00 (+4.23%)
Log in

NASDAQ:VRCAVerrica Pharmaceuticals Stock Price, Forecast & News

Add
Compare
Today's Range N/A
50-Day Range
$6.48
MA: $9.44
$15.12
52-Week Range N/A
Volume137,273 shs
Average Volume223,096 shs
Market Capitalization$171.93 million
P/E RatioN/A
Dividend YieldN/A
Beta2.08
Verrica Pharmaceuticals Inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The company's lead product candidate include VP-102 that is in phase III clinical trial for the treatment of molluscum contagiosum; in phase II clinical trial for the treatment of common warts; and completed phase I clinical trial for the treatment of Genital warts. It is also developing cantharidin-based product candidate, VP-103 for the treatment of plantar warts. The company was founded in 2013 and is headquartered in West Chester, Pennsylvania.
Read More
Verrica Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.3Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.52 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VRCA
CUSIPN/A
CIKN/A
Phone484-453-3300

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.52 per share

Profitability

Net Income$-28,210,000.00

Miscellaneous

Employees16
Market Cap$171.93 million
Next Earnings Date11/4/2020 (Estimated)
OptionableNot Optionable
30 days | 90 days | 365 days | Advanced Chart

Receive VRCA News and Ratings via Email

Sign-up to receive the latest news and ratings for VRCA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Verrica Pharmaceuticals (NASDAQ:VRCA) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Verrica Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verrica Pharmaceuticals in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Verrica Pharmaceuticals
.

When is Verrica Pharmaceuticals' next earnings date?

Verrica Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Verrica Pharmaceuticals
.

How were Verrica Pharmaceuticals' earnings last quarter?

Verrica Pharmaceuticals Inc (NASDAQ:VRCA) issued its earnings results on Wednesday, August, 5th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.07.
View Verrica Pharmaceuticals' earnings history
.

What price target have analysts set for VRCA?

5 analysts have issued twelve-month price objectives for Verrica Pharmaceuticals' shares. Their forecasts range from $10.00 to $18.00. On average, they expect Verrica Pharmaceuticals' stock price to reach $15.00 in the next year.
View analysts' price targets for Verrica Pharmaceuticals
.

Has Verrica Pharmaceuticals been receiving favorable news coverage?

Media stories about VRCA stock have trended neutral on Tuesday, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Verrica Pharmaceuticals earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future.
View the latest news about Verrica Pharmaceuticals
.

Are investors shorting Verrica Pharmaceuticals?

Verrica Pharmaceuticals saw a increase in short interest in the month of July. As of July 31st, there was short interest totaling 1,040,000 shares, an increase of 25.2% from the July 15th total of 830,400 shares. Based on an average trading volume of 95,300 shares, the short-interest ratio is currently 10.9 days. Currently, 8.1% of the company's shares are sold short.
View Verrica Pharmaceuticals' Short Interest
.

Who are some of Verrica Pharmaceuticals' key competitors?

What other stocks do shareholders of Verrica Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Verrica Pharmaceuticals investors own include Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), CBL & Associates Properties (CBL), Gran Tierra Energy (GTE), Novan (NOVN), Pennsylvania R.E.I.T. (PEI), OrganiGram (OGI) and Zosano Pharma (ZSAN).

Who are Verrica Pharmaceuticals' key executives?

Verrica Pharmaceuticals' management team includes the following people:
  • Mr. Ted White, Pres, CEO & Director (Age 54)
  • Mr. Chris Degnan, Chief Financial Officer (Age 39)
  • Mr. Joe Bonaccorso, Chief Commercial Officer (Age 55)
  • Dr. Patrick Burnett M.D., Ph.D., Chief Medical Officer (Age 47)
  • Christopher G. Hayes, Sec.

When did Verrica Pharmaceuticals IPO?

(VRCA) raised $75 million in an initial public offering (IPO) on Friday, June 15th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen acted as the underwriters for the IPO.

What is Verrica Pharmaceuticals' stock symbol?

Verrica Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRCA."

Who are Verrica Pharmaceuticals' major shareholders?

Verrica Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Kornitzer Capital Management Inc. KS (1.90%), Creative Planning (0.08%), Spouting Rock Asset Management LLC (0.06%) and UBS Group AG (0.03%). Company insiders that own Verrica Pharmaceuticals stock include Linda Palczuk, Matt Davidson, Paul B Manning, Sean Stalfort and Ted White.
View institutional ownership trends for Verrica Pharmaceuticals
.

Which major investors are selling Verrica Pharmaceuticals stock?

VRCA stock was sold by a variety of institutional investors in the last quarter, including Spouting Rock Asset Management LLC, and UBS Group AG.
View insider buying and selling activity for Verrica Pharmaceuticals
.

Which major investors are buying Verrica Pharmaceuticals stock?

VRCA stock was acquired by a variety of institutional investors in the last quarter, including Creative Planning, and Kornitzer Capital Management Inc. KS. Company insiders that have bought Verrica Pharmaceuticals stock in the last two years include Linda Palczuk, Paul B Manning, Sean Stalfort, and Ted White.
View insider buying and selling activity for Verrica Pharmaceuticals
.

How do I buy shares of Verrica Pharmaceuticals?

Shares of VRCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

How big of a company is Verrica Pharmaceuticals?

Verrica Pharmaceuticals has a market capitalization of $0.00. The company earns $-28,210,000.00 in net income (profit) each year or ($1.13) on an earnings per share basis. Verrica Pharmaceuticals employs 16 workers across the globe.

What is Verrica Pharmaceuticals' official website?

The official website for Verrica Pharmaceuticals is www.verrica.com.

How can I contact Verrica Pharmaceuticals?

Verrica Pharmaceuticals' mailing address is 10 NORTH HIGH STREET SUITE 200, WEST CHESTER PA, 19380. The company can be reached via phone at 484-453-3300 or via email at [email protected]

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.